Engineering Preparedness for Biological Threats
Elusys Therapeutics develops medical countermeasures against bioterrorism and high-consequence biological threats. We confront a singular operational challenge: engineer therapies for rare, severe, and potentially catastrophic agents before they become urgent national priorities. This demands uncompromising scientific discipline, regulatory expertise, and an acute understanding of emergency-response requirements.
Our Mission
Therapies or Threats That Cannot Be Ignored
Elusys closes critical gaps in the national biodefense architecture. We focus on Category A pathogens capable of producing rapid, high-mortality disease and destabilizing public health systems. Our therapies are not theoretical constructs; they are designed for real-world deployment in environments where time, logistics, and clinical uncertainty converge.
Category A Focus
Why These Agents Demand Unrelenting Attention
The Centers for Disease Control and Prevention designates Category A agents as the most dangerous because they can be easily disseminated or transmitted person-to-person, result in high case-fatality rates (often >40%), cause major public health impact, provoke widespread panic and social disruption, and demand specialized preparedness infrastructure. These agents include: • Anthrax — Bacillus anthracis • Botulism — botulinum toxin • Plague — Yersinia pestis • Smallpox — variola virus • Tularemia — Francisella tularensis • Viral hemorrhagic fevers — including Ebola, Marburg, Lassa, and related viruses
Why Therapies Are Needed
Exposure Happens Before the Alarm
In a deliberate attack or accidental release, symptomatic patients are often the first—and only—warning. Diagnostic confirmation lags by hours or days; the therapeutic window closes rapidly. Preparedness demands immediate, post-exposure medical countermeasures that can be prepositioned in national stockpiles and administered under austere conditions to save lives when prevention is no longer an option.
Our Experience
Proven Execution in High-Consequence Biodefense
Elusys has advanced ANTHIM® (obiltoxaximab) from concept through full regulatory licensure in the United States and Canada, culminating in multiple deliveries to national stockpiles. This end-to-end achievement—from preclinical development and to commercial-scale manufacturing and government procurement—establishes the operational template for every program we undertake.
Our Capabilities
Monoclonal antibody development calibrated to complex biothreat toxins and pathogens
Expert navigation of biodefense regulatory pathways, including the FDA Animal Rule and Emergency Use Authorization frameworks
Domestic manufacturing coordination and supply-chain resilience for emergency-use environments
Strategic partnerships with U.S. government agencies (e.g., BARDA, Strategic National Stockpile) and international preparedness authorities
Integrated support for national stockpile planning, deployment logistics, and surge-capacity readiness
